EACR 2025: A look into next-generation strategies in cancer
At the Annual Congress of the European Association for Cancer Research (EACR) in Lisbon, multiple sessions aimed to provide fresh perspectives on the always challenging treatment of cancer, with a strong focus on innovative strategies.

EACR 2025: A look into next-generation strategies in cancer
At the Annual Congress of the European Association for Cancer Research (EACR) in Lisbon, multiple sessions aimed to provide fresh perspectives on the always challenging treatment of cancer, with a strong focus on innovative strategies.
Bovine adenoviral vector-based bivalent vaccine protects mice and ferrets from influenza A and B
Researchers from Purdue University and the U.S. Centers for Disease Control and Prevention have recently developed a novel influenza vaccine candidate that uses a bovine adenoviral (BAd) vector to deliver nucleoprotein (NP) antigens from both influenza A and B viruses, along with an autophagy-inducing peptide (C5) to enhance cellular immune responses, particularly T-cell responses.
New RNAi targets KRAS G12V using a cancer cell receptor
An RNA interference (RNAi) molecule that selectively targets the KRAS G12V mutation could represent a key advance in the treatment of cancer associated with this oncogenic variant. Researchers at the University of North Carolina (UNC) at Chapel Hill, in collaboration with Enfuego Therapeutics Inc., have developed a new RNAi designed to enter cells through the epidermal growth factor receptor (EGFR), which is commonly overexpressed in tumor cells. This targeted entry pathway could minimize the side effects associated with therapies that affect KRAS.
MLK3 degrader PROTAC reduces oncogenic potential of TNBC cells
Researchers from the National Cancer Institute and their collaborators have presented data regarding a MLK3-degrading PROTAC, CEP1347-VHL-02, for treating triple-negative breast cancer.
Chinese scientists patent new EED degradation inducers
Researchers at Shanghai Haiyan Pharmaceutical Technology Co. Ltd. and Yangtze River Pharmaceutical Group have disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to a polycomb protein EED-targeting moiety through linkers; they are reported to be useful for the treatment of cancer.
COG5 unveiled as a therapeutic target in multiple myeloma
Multiple myeloma bone disease (MBD) lacks effective biomarkers; recent evidence involves exosomal circRNAs in the progression of cancer, but their roles in the field have not been deeply explored. The aim of this study was to explore the role of component of oligomeric golgi complex 5 (COG5) and shed light on its osteolytic mechanism.

BioWorld Insider Podcast

Robert Williamson, CEO of Triumvira Immunologics, and Hernan Bazan, CEO of South Rampart Pharma, discuss bracing for tariffs, NIH grant cuts and gifting China a biopharma leadership position.

Listen now

Conferences

BAL-0891 induces potent antileukemic effect in preclinical AML
European Hematology Association
Sillajen Inc. has recently presented data regarding their threonine tyrosine kinase (TTK) and Polo-like kinase 1 (PLK1) dual inhibitor BAL-0891 as a therapeutic approach for acute myeloid leukemia (AML) treatment. The compound was tested both in vitro and in vivo in the preclinical setting.
AZD-1390 + T-DXd shows synergy reducing tumor growth in TNBC
Cancer
About 30%-40% of triple-negative breast cancers (TNBC) show HER2-low status and may benefit from the HER2-directed antibody-drug conjugate trastuzumab deruxtecan (T-DXd). Ataxia-telangiectasia mutated (ATM) kinase plays a crucial role in double-strand break (DSB) repair response, thus inhibitors of...
HPK1 inhibitor BGB-15025 exerts antileukemic activity in mice
European Hematology Association
Despite an initial complete remission of 60%-80% in patients receiving anthracycline/cytarabine induction, acute myeloid leukemia (AML) shows a suboptimal long-term outcome rate. Serine/threonine kinase HPK1 has emerged as a promising therapeutic target, demonstrating pan-cancer prognostic...
SAN-523 demonstrates anti-inflammatory efficacy in preclinical models of microcrystalline arthropathies
Musculoskeletal
University of Lausanne has reported promising preclinical data on SAN-523, a first-in-class positive allosteric modulator of cystathionine gamma-lyase (CSE), developed as a potential therapeutic for microcrystalline arthropathies, including gout and calcium pyrophosphate deposition (CPPD) disease.

Cancer

DNA vaccine against high-grade serous ovarian cancer
Immuno-oncology
Researchers at Queen’s University of Belfast and collaborators have developed a DNA vaccine against high-grade serous ovarian cancer. The vaccine encodes PRAME, which the researchers found to be upregulated in several cohorts of patients with the malignancy.

Infection

Researchers develop NSP8-derived peptides successfully targeting SARS-CoV-2 replication machinery
Coronavirus
Researchers from the Institute for Basic Science of Korea and collaborating institutions have designed a new class of peptide-based inhibitors targeting a crucial interface within the SARS-CoV-2 replication complex, offering a potential new avenue for antiviral therapy.

European researchers divulge new ECF inhibitors
Patents
Scientists at Helmholtz Zentrum für Infektionsforschung GmbH, Rijksuniversiteit Groningen and Université de Lausanne have synthesized energy-coupling factor (ECF) transporter (bacterial) inhibitors reported to be useful for the treatment of enterococcal and streptococcal infections.
Gates Foundation grant supports Octant’s new program in HPV-related cancers
Cancer
Octant Inc. has received a $4.9 million grant from the Gates Foundation to support a new therapeutics program focused on human papillomavirus (HPV)-related cancers. The initiative will develop affordable, broad-spectrum, small-molecule antiviral drugs designed to disrupt the interaction between...

Neurology/psychiatric

University of Sydney divulges new TSPO ligands
Patents
University of Sydney has synthesized translocator protein (TSPO; PBR) (A147T mutant) ligands reported to be useful for the diagnosis and treatment of neurological disorders.
Biogen patents new HTT splicing modulators
Patents
Biogen Inc. has disclosed huntingtin (HTT; HD) (mutant) splicing modulators reported to be useful for the treatment of Huntington’s disease and spinal muscular atrophy (SMA).
TMEM119 clears amyloid beta deposits in AD mice
Conferences
Alzheimer’s disease (AD) progression involves microglial activation, and restoring or maintaining microglia homeostasis is a therapeutic approach to fight against AD.
Centessa’s OX2R agonist ORX-142 gains IND clearance
Regulatory
Centessa Pharmaceuticals plc has obtained IND clearance from the FDA to initiate a phase I study of ORX-142 in healthy volunteers. ORX-142 is an investigational, novel, highly potent and selective OX2R agonist being developed for the treatment of select neurological and neurodegenerative disorders.
Nanjing Mingde New Drug Research discovers new KCNQ2/3 activators
Patents
Nanjing Mingde New Drug Research Co. Ltd. has described potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators reported to be useful for the treatment of epilepsy.

Endocrine/metabolic

PPRHs lower levels of PCSK9 and cholesterol in transgenic mouse without causing toxicity
Cardiovascular
Researchers from the Universitat de Barcelona and Oregon Health & Science University have developed a novel gene silencing technique using polypurine reverse Hoogsteen hairpins (PPRH) to target and inhibit the expression of PCSK9.

Biomarkers

Taurine aging biomarker story gets more complicated
Science
A publication based on longitudinal and cross sectional data and led by researchers at the U.S. NIH’s National Institute on Aging published on June 5, 2025, in Science has stated that the impact of taurine supplementation at delaying aging or treating aging-related conditions is context-dependent,...

MCTP2 induces oral cancer progression and metastasis
Cancer
Head and neck cancer is the sixth most common cancer worldwide, and oral squamous cell carcinoma (OSCC) accounts for about 2% of all cancers and 1.9% of cancer-related deaths globally. OSCC is characterized by local invasiveness and lymph node metastatic ability, making it a very malignant cancer.
FFAR4 as biomarker of glomerular injury and aging
Aging
Researchers have discovered that reduced expression of the free fatty acid receptor 4 (FFAR4) is a biomarker of podocyte injury and aging, as well as a therapeutic target. Podocyte injury leads to progression of glomerular disease and aging, but the underlying mechanisms are poorly understood.

Gastrointestinal

Engineered anti-IL-23 receptor antibody enables oral delivery to treat inflammatory bowel disease
Antibody
Researchers from Genentech Inc. have developed a novel single-domain antibody (VHH) targeting the IL-23 signaling pathway, which can be administered orally to effectively treat inflammatory bowel disease in animal models.
Gut microbiome leads to metabolic and immune changes after transplant
Science
Is fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of Chicago have investigated the regional differences in gut environments to question these interventions.
Korean scientists divulge new ADAMTS4 inhibitors for hepatic fibrosis
Patents
Researchers at Gachon University and Seoul National University Hospital have synthesized a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4; aggrecanase-1) inhibitors reported to be useful for the treatment of hepatic fibrosis.
New LPAM-1 antagonists disclosed in Dice Molecules patent
Patents
Dice Molecules SV LLC has divulged integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of graft-vs.-host disease, type 1 diabetes, inflammatory bowel disease, colitis and primary sclerosing cholangitis.
Gut microbiome leads to metabolic and immune changes after transplant
Science
Is fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of Chicago have investigated the regional differences in gut environments to question these interventions to analyze the...
17β-HSD13 inhibitors described in Astrazeneca patent
Patents
Astrazeneca AB has reported the identification of 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH; MASH), among others.

podcast microphone, sound waves on purple background Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.

Recent episodes:

View all

BioWorld

The news source of record covering the development of innovative human therapies for 25+ years

BioWorld MedTech

Actionable and timely intelligence on advances in medical devices and technologies for 20+ years

BioWorld Asia

A weekly monitor of biopharmaceutical news from the industry’s fastest-growing region

BioWorld Science

Essential discovery and preclinical research news to support crucial drug R&D decisions at the earliest stages

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription

Today's news in brief

BioWorld

BioWorld MedTech

BioWorld Asia

BioWorld Science

BioWorld Premium